Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Saint Paul Press.
Press releases published on June 30, 2025

New Book Release: 'God And The Narrow Gate' by Edward G. Palmer Explores Eternal Life and Spiritual Truths
MAPLE GROVE, MN, UNITED STATES, June 30, 2025 /EINPresswire.com/ -- Author Edward G. Palmer proudly presents his latest literary masterpiece, "God And The Narrow Gate: How to Enter Eternal Life and Not Get Picked Up on the Last Day." This groundbreaking …

Northwoods Haven Recovery Reinforces Commitment to Combat Fentanyl Addiction Following National Awareness Day
Outpatient Treatment Center in Minneapolis Offers Specialized Programs for Fentanyl and Other Substance Addictions MINNEAPOLIS, MN, UNITED STATES, June 30, 2025 /EINPresswire.com/ -- In the wake of National Fentanyl Awareness Day on April 29, 2025, …

Bright Line Investigations Earns MN Agency License and State Approval to Deliver Certified Training Programs
Bright Line Investigations obtains MN detective agency license and full training course approval, expanding multi-state leadership in investigative education. MINNEAPOLIS–ST. PAUL, MN, UNITED STATES, June 30, 2025 /EINPresswire.com/ -- Bright Line …

CodaPet expands compassionate in-home pet euthanasia services in Minneapolis, MN
The veterinarian-owned startup empowers a network of veterinarians who provide in-home euthanasia to ease the passing of pets at home, surrounded by loved ones. MINNEAPOLIS, MN, UNITED STATES, June 30, 2025 /EINPresswire.com/ -- CodaPet has expanded its …

Sezzle Unveils Smarter Shopping Tools to Meet Rising Consumer Expectations
Minneapolis, MN, June 30, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ: SEZL) (Sezzle or Company) // - Sezzle, the purpose‑driven digital payment platform, today launches a suite of new features to help consumers navigate increasing financial pressure. …

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”), the six-month radiographic progression free survival (“rPFS”) rate was 66% • In a …